Checkpoint immunotherapy for cancer: Superior survival, unaccustomed toxicities

Internal Medicine Journal

Volumn 45, Issue 7, 2015, Pages 696-701

  Gedye, C ^a,b   van der Westhuizen, A ^b   John, T ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Cancer; Checkpoint protein; Immune related side effect; Immunotherapy; Lung cancer; Melanoma

Indexed keywords

CANCER ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1;

ABDOMINAL DISCOMFORT; AUTOIMMUNE DISEASE; BLOATING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; INTESTINE PERFORATION; MANAGED CARE; MESOTHELIOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; SMALL CELL LUNG CANCER; ADVERSE EFFECTS; GENE; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; NEOPLASMS; PROCEDURES; SURVIVAL RATE;

GENES, CDC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SURVIVAL RATE;

EID: 84933521071     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12653     Document Type: Review

References (20)

1. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007; 5: 994-1006.
2. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1): S11-14.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C etal. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
5. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M etal. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15: 2507-2513.
6. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C etal. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
7. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R etal. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-2054.
8. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D etal. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14: 1104-1111.
9. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M etal. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31: 616-622.
10. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R etal. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24: 75-83.
11. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
12. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH etal. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
14. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH etal. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
15. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM etal. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
16. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R etal. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
17. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD etal. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer 2010; 116: 1767-1775.
18. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS etal. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2: 127-132.
19. Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH etal. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-5074.
20. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24: 321-325.